Get the Stockscreener App
22.41
5.25%
-1.215
Rapport Therapeutics Inc stock is traded at $22.41, with a volume of 38,429.
It is down -5.25% in the last 24 hours and up +7.60% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$23.62
Open:
$23.49
24h Volume:
38,429
Relative Volume:
0.27
Market Cap:
$839.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.79%
1M Performance:
+7.60%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$22.27
$23.59
1-Week Range:
$22.27
$27.48
52-Week Range:
$16.55
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics to Present at Stifel Healthcare - GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November - StockTitan
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Still a Buy? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
SG Americas Securities LLC Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) Trading Report - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.2%Here's Why - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownShould You Sell? - MarketBeat
Jones Trading Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7%Time to Sell? - MarketBeat
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - MSN
When (RAPP) Moves Investors should Listen - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Millennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Up 32.4% in September - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3%What's Next? - MarketBeat
75,516 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by The Manufacturers Life Insurance Company - MarketBeat
Two more Mass. biotechs raise $330M in IPOs, to debut on Nasdaq - The Business Journals
(RAPP) On The My Stocks Page - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 7%Should You Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.1% - MarketBeat
Logos Global Management LP Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Perceptive Advisors LLC Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 6.2% Higher - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
ARCH Venture Management LLC Makes New $86.73 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
ARCH Venture Management LLC Invests $86.73 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
GC Therapeutics Raises $65M Series A - citybiz
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans - The Business Journals
Rapport Therapeutics Inc. (RAPP) rating initates by TD Cowen - Knox Daily
GC Therapeutics Raises $65M in Series A Funding - FinSMEs
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 2.4% - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 4.7% - Defense World
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright - TipRanks
Quest Partners LLC Sells 5,882 Shares of iRobot Co. (NASDAQ:IRBT) - Defense World
Sofinnova Investments Inc. Invests $45.39 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 4.7% Higher - MarketBeat
RNAZ’s Financial Health: Exploring TransCode Therapeutics Inc’s Debt-to-Equity Ratio of 1.79 - The InvestChronicle
Trimble and Platform Science pushed hard to get deal done before Vegas meeting - Yahoo Finance
Johnson & Johnson Invests $58.11 Million in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $19.00 - MarketBeat
(RAPP) Trading Advice - Stock Traders Daily
TD Asset Management Inc Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
TD Asset Management Inc Invests $2.36 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Shares of two Mass. biotech IPOs rise on first day of trading - The Business Journals
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.5% - MarketBeat
The Potential Rise in the Price of Rapport Therapeutics Inc. (RAPP) following insiders activity - Knox Daily
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $21.20 - MarketBeat
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences - GlobeNewswire
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEALY JAMES | Director |
Jun 10 '24 |
Buy |
17.00 |
558,824 |
9,500,008 |
1,863,327 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):